Highlights and Quick Summary
- Research and Development Expense of Revenue for the quarter ending June 30, 2022 was 18.01% (a -26.13% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development Expense of Revenue decreased by -39.26%
- Annual Research and Development Expense of Revenue for 2021 was 24.35% (a 0.83% increase from previous year)
- Annual Research and Development Expense of Revenue for 2021 was 24.15% (a 53.04% increase from previous year)
- Annual Research and Development Expense of Revenue for 2020 was 15.78% (a 0.77% increase from previous year)
- Twelve month Research and Development Expense of Revenue ending June 30, 2022 was 23.64% (a -3.15% decrease compared to previous quarter)
- Twelve month trailing Research and Development Expense of Revenue increased by 12.57% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
| 30 Jun '22 | 31 Mar '22 | 31 Dec '21 | 30 Sep '21 |
|---|---|---|---|
| 23.64% | 24.41% | 24.34% | 21.0% |
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development Expense of Revenue of Biofrontera AG Sponsored ADR
Most recent Research and Development Expense of Revenueof BFAGY including historical data for past 10 years.Interactive Chart of Research and Development Expense of Revenue of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | – | 18.01% | 24.38% | – |
| 2021 | 24.17% | 29.65% | 21.06% | 24.04% | 24.35% |
| 2020 | 14.56% | 21.52% | 11.18% | 20.25% | 15.78% |
| 2019 | – | 11.64% | 17.34% | 15.98% | 14.83% |
| 2018 | – | – | – | 18.47% | 20.97% |
| 2017 | – | – | 45.0% | 43.08% | 35.13% |
| 2016 | 0.0% | – | – | – | 75.69% |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic